Evidence map›Paper›PMID 27114914›Full record

ArticleMolecular genetics and metabolism reports2016

A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II.

Elsa G Shapiro, Kyle Rudser, Alia Ahmed, Robert D Steiner, Kathleen A Delaney, Brianna Yund, Kelly King, Alicia Kunin-Batson, Julie Eisengart, Chester B Whitley

Registry-linked trialAbstract read
In one paragraph

Article in Molecular genetics and metabolism reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01870375 (Longitudinal Studies of Brain Structure and Function in MPS Disorders), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01870375 completednot on this map

Longitudinal Studies of Brain Structure and Function in MPS Disorders

TypeobservationalSponsorUniversity of MinnesotaRan2009 to 2019Enrolled100ConditionsMucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis Type IV
3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Innate Immunity in Mucopolysaccharide Diseases.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elsa G ShapiroDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Kyle RudserDivision of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Alia AhmedDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Robert D SteinerDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
Kathleen A DelaneyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Brianna YundDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Kelly KingDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Alicia Kunin-BatsonHealthPartners Institute, Minneapolis, MN, USA.
Julie EisengartDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Chester B WhitleyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

Funding

Training & EducationU54NS065768 · NINDS · UNIVERSITY OF MINNESOTA · PI WHITLEY, CHESTER B. · 2009 to 2024
$17.7M
NINDS NIH HHS U54 NS065768
6 · The paper itself

Abstract

objectivesThe behavioral, adaptive and quality of life characteristics of attenuated mucopolysaccharidosis type II (MPS II) have not been well studied. Understanding changes over time in the attenuated phenotype may assist in helping achieve better outcomes in long-term function. This longitudinal study investigates these outcomes in relation to age, somatic disease burden, and IQ. Specifically, somatic disease burden is a major challenge for these patients, even with treatment with enzyme replacement therapy.

methods15 patients, 10 between ages 6 and < 12 and 5 between ages ≥ 12 and 18, were selected who had at least 2 yearly visits. The occurrence of physical signs, the Physical Symptom Score, and IQ in these two groups was studied as well as the longitudinal association of age with standardized measures of quality of life, adaptive function, and behavioral symptoms as rated by parents and the child's self-report. Slopes by age across and within patients were calculated for these measures.

resultsAll but one child had hearing loss, most had joint contractures and short stature. Somatic disease burden increased with age. IQ, although normal for most, also improved with age in those under 12 years of age. Physical quality of life decreased while psychosocial quality of life increased with age. Although other adaptive skills were in the broad average range, daily living skills were low at baseline relative to normative data and decreased over time. Behavior ratings indicated improvement in attention and hyperactivity over time. No patient had severe psychopathology, but older children reported an increasing sense of inadequacy and low self-esteem on self-report, presumably due to increasing awareness of differences from peers over time.

conclusionsAttenuated MPS II patients have increasing somatic disease burden and poor physical quality of life as they develop as well as decreasing self-esteem and sense of adequacy. Psychosocial quality of life, adaptive skills, and attention improve. Recognition of and intervention around these issues will be beneficial to MPS II attenuated patients who have the resources to use such assistance to improve their long-term outcomes.

Indexed as

Adaptive functionsAttenuated mucopolysaccharidosis type IIBehavioral outcomesQuality of life

Identifiers

PMID27114914
PMCPMC4832084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.